ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RIGL vs MLTX // NET PROFIT MARGIN

Rigel Pharmaceuticals Inc. (NASDAQ) VS. MoonLake Immunotherapeutics (Class A) (NASDAQ) • 15-METRIC TALLY: RIGL 4 — MLTX 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RIGL VS. MLTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RIGL MLTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 93.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 28.20% -35.00% +63.20 RIGL /roic <GO>
EV/EBITDA & P/E Valuation 7.3x — — TIE /valuation <GO>
Free Cash Flow Yield 7.87% -18.33% +26.20 RIGL /fcf-yield <GO>
Operating Margin 42.60% — — TIE /operating-margins <GO>
Net Profit Margin ACTIVE 68.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 64.10% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.64 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 2/9 +5.00 RIGL /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 63.9 50.0 +13.90 RIGL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $958.5M $1.00B -$44.1M MLTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RIGL REV MLTX REV RIGL GROSS % MLTX GROSS % RIGL FCF MLTX FCF
FY 2025 $294.3M $685.5M 93.3% — $75.7M -$196.0M
FY 2024 $179.3M $400.7M 89.6% — $31.5M -$117.1M
FY 2023 $116.9M $151.5M — — -$5.7M -$42.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RIGL // BETA —
MLTX // BETA —